Abstract
Secukinumab treatment shows a neutral effect on the lipid profile of patients with moderate to severe plaque psoriasis: Results from a randomized, double-blind, placebo-controlled, phase II study
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have